Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III Study

Yan Zhao(Peking University), Elizabeth Laws(Sanofi (United States)), John T. O’Malley(Brigham and Women's Hospital), Shelley Li(Sanofi (United States)), Songmei Geng(Second Affiliated Hospital of Xi'an Jiaotong University), Xiaohong Zhu(First Affiliated Hospital of Wenzhou Medical University), Zhiqiang Song(Army Medical University), Christine Xu(Sanofi (United States)), Qianjin Lu(Central South University), Ningning Dang(Shandong Provincial Hospital), Xing‐Hua Gao(First Hospital of China Medical University), Jun Gu(Peking University), Liming Wu(Hangzhou First People's Hospital), Ashish Bansal(Regeneron (United States)), Xu Yao(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Li(Xuzhou Medical College), Min Wang(Anhui Medical University), Linfeng Li(Beijing Tongren Hospital), Xiaoming Liu(Peking University Shenzhen Hospital), Chunlei Zhang(Peking University), Lingling Liu(The First People's Hospital of Shunde), Jinyan Wang(Ningbo No. 2 Hospital), Yifeng Guo(Shanghai Jiao Tong University), Quanzhong Liu(Tianjin Medical University General Hospital), Nikhil Amin(Regeneron (United States)), Yangfeng Ding(Shanghai Skin Disease Hospital), Li Dong(Sanofi (China))
International Journal of Dermatology and Venereology
October 11, 2022
Cited by 4


Related Papers